Do analysts prefer CELU or ICCC?

Celularity currently has a consensus price target of $6.00, suggesting a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher possible upside, research analysts clearly believe Celularity is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, CELU or ICCC?

ImmuCell has higher revenue and earnings than Celularity. ImmuCell is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celularity $26.55M 0.83 -$91.72M -$3.33 N/A ImmuCell $27.64M 3.19 -$1.04M -$0.06 N/A

Is CELU or ICCC more profitable?

ImmuCell has a net margin of -1.82% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% ImmuCell -1.82% -1.88% -1.22%

Do analysts recommend CELU or RLYB?

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher possible upside, research analysts clearly believe Celularity is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELU or RLYB more profitable?

Celularity has a net margin of -345.45% compared to Rallybio's net margin of -911.07%. Celularity's return on equity of 0.00% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Rallybio -911.07% -55.79% -51.48%

Is CELU or BMEA more profitable?

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Biomea Fusion N/A -265.37% -103.96%

Do analysts recommend CELU or CYPH?

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher probable upside, equities analysts clearly believe Celularity is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend JATT or CELU?

Celularity has a consensus target price of $6.00, indicating a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, JATT or CELU?

JATT Acquisition has higher earnings, but lower revenue than Celularity. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Celularity $26.55M 0.83 -$91.72M -$3.33 N/A

Celularity (CELU) Competitors

$0.76 +0.01 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$0.76 +0.00 (+0.13%)

As of 07:28 PM Eastern

Compare

CELU vs. ICCC, RLYB, BMEA, CYPH, and JATT

Should you buy Celularity stock or one of its competitors? MarketBeat compares Celularity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celularity include ImmuCell (ICCC), Rallybio (RLYB), Biomea Fusion (BMEA), Cypherpunk Technologies (CYPH), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.

How does Celularity compare to ImmuCell?

Celularity (NASDAQ:CELU) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Celularity has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

ImmuCell has a net margin of -1.82% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
ImmuCell	-1.82%	-1.88%	-1.22%

19.0% of Celularity shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 5.7% of ImmuCell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ImmuCell had 1 more articles in the media than Celularity. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for Celularity. Celularity's average media sentiment score of 0.00 equaled ImmuCell'saverage media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
ImmuCell	Neutral

ImmuCell has higher revenue and earnings than Celularity. ImmuCell is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.83	-$91.72M	-$3.33	N/A
ImmuCell	$27.64M	3.19	-$1.04M	-$0.06	N/A

Celularity currently has a consensus price target of $6.00, suggesting a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher possible upside, research analysts clearly believe Celularity is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ImmuCell beats Celularity on 8 of the 15 factors compared between the two stocks.

How does Celularity compare to Rallybio?

Celularity (NASDAQ:CELU) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher possible upside, research analysts clearly believe Celularity is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Celularity has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Rallybio has a beta of -0.89, suggesting that its share price is 189% less volatile than the broader market.

Celularity has a net margin of -345.45% compared to Rallybio's net margin of -911.07%. Celularity's return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Rallybio	-911.07%	-55.79%	-51.48%

In the previous week, Celularity's average media sentiment score of 0.00 equaled Rallybio'saverage media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Rallybio	Neutral

Rallybio has lower revenue, but higher earnings than Celularity. Rallybio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.83	-$91.72M	-$3.33	N/A
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A

19.0% of Celularity shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Celularity beats Rallybio on 10 of the 14 factors compared between the two stocks.

How does Celularity compare to Biomea Fusion?

Celularity (NASDAQ:CELU) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Biomea Fusion has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Biomea Fusion	N/A	-265.37%	-103.96%

In the previous week, Biomea Fusion had 1 more articles in the media than Celularity. MarketBeat recorded 1 mentions for Biomea Fusion and 0 mentions for Celularity. Celularity's average media sentiment score of 0.00 equaled Biomea Fusion'saverage media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Biomea Fusion	Neutral

Biomea Fusion has lower revenue, but higher earnings than Celularity. Biomea Fusion is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.83	-$91.72M	-$3.33	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

19.0% of Celularity shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 17.3% of Celularity shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Celularity currently has a consensus target price of $6.00, indicating a potential upside of 691.56%. Biomea Fusion has a consensus target price of $8.50, indicating a potential upside of 591.06%. Given Celularity's higher possible upside, analysts plainly believe Celularity is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Celularity has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market.

Summary

Celularity and Biomea Fusion tied by winning 7 of the 14 factors compared between the two stocks.

How does Celularity compare to Cypherpunk Technologies?

Celularity (NASDAQ:CELU) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher probable upside, equities analysts clearly believe Celularity is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cypherpunk Technologies has lower revenue, but higher earnings than Celularity. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.83	-$91.72M	-$3.33	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

In the previous week, Celularity's average media sentiment score of 0.00 equaled Cypherpunk Technologies'average media sentiment score.

Company	Overall Sentiment
Celularity	Neutral
Cypherpunk Technologies	Neutral

Cypherpunk Technologies has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Celularity has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Celularity beats Cypherpunk Technologies on 8 of the 13 factors compared between the two stocks.

How does Celularity compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, JATT Acquisition's average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score.

Company	Overall Sentiment
JATT Acquisition	Neutral
Celularity	Neutral

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

JATT Acquisition has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Celularity	-345.45%	N/A	-77.94%

JATT Acquisition has higher earnings, but lower revenue than Celularity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Celularity	$26.55M	0.83	-$91.72M	-$3.33	N/A

Celularity has a consensus target price of $6.00, indicating a potential upside of 691.56%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

JATT Acquisition and Celularity tied by winning 5 of the 10 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.78M	$3.41B	$6.43B	$12.54B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.23	19.52	24.98	24.33
Price / Sales	0.83	330.92	529.24	114.72
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	-0.57	8.34	10.85	6.58
Net Income	-$91.72M	$23.80M	$3.56B	$336.75M
7 Day Performance	-1.56%	3.63%	0.70%	-0.49%
1 Month Performance	-12.88%	1.77%	0.29%	1.56%
1 Year Performance	-56.93%	58.60%	30.68%	33.78%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	3.1632 of 5 stars	$0.76 +0.8%	$6.00 +691.6%	-57.3%	$21.78M	$26.55M	N/A	220	Gap Down
ICCC ImmuCell	0.9222 of 5 stars	$9.38 -1.6%	N/A	+24.9%	$84.86M	$29.93M	N/A	70
RLYB Rallybio	0.2469 of 5 stars	$15.90 flat	N/A	+551.3%	$84.27M	$860K	N/A	40
BMEA Biomea Fusion	1.6841 of 5 stars	$1.16 -3.3%	$8.50 +632.8%	-34.8%	$83.87M	N/A	N/A	50	Positive News
CYPH Cypherpunk Technologies	0.2146 of 5 stars	$0.79 -3.3%	N/A	+94.5%	$83.67M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. ICCC, RLYB, BMEA, CYPH, and JATT

How does Celularity compare to ImmuCell?

Summary

How does Celularity compare to Rallybio?

Summary

How does Celularity compare to Biomea Fusion?

Summary

How does Celularity compare to Cypherpunk Technologies?

Summary

How does Celularity compare to JATT Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. ICCC, RLYB, BMEA, CYPH, and JATT

How does Celularity compare to ImmuCell?

Which has more risk and volatility, CELU or ICCC?

Is CELU or ICCC more profitable?

Do insiders & institutionals have more ownership in CELU or ICCC?

Does the media refer more to CELU or ICCC?

Which has preferable earnings and valuation, CELU or ICCC?

Do analysts prefer CELU or ICCC?

Summary

How does Celularity compare to Rallybio?

Do analysts recommend CELU or RLYB?

Which has more risk and volatility, CELU or RLYB?

Is CELU or RLYB more profitable?

Does the media favor CELU or RLYB?

Which has stronger earnings & valuation, CELU or RLYB?

Do insiders and institutionals believe in CELU or RLYB?

Summary

How does Celularity compare to Biomea Fusion?

Is CELU or BMEA more profitable?

Does the media favor CELU or BMEA?

Which has better valuation & earnings, CELU or BMEA?

Do insiders & institutionals believe in CELU or BMEA?

Do analysts recommend CELU or BMEA?

Which has more risk & volatility, CELU or BMEA?

Summary

How does Celularity compare to Cypherpunk Technologies?

Do analysts recommend CELU or CYPH?

Which has higher earnings and valuation, CELU or CYPH?

Does the media refer more to CELU or CYPH?

Is CELU or CYPH more profitable?

Which has more volatility & risk, CELU or CYPH?

Do institutionals and insiders believe in CELU or CYPH?

Summary

How does Celularity compare to JATT Acquisition?

Does the media refer more to JATT or CELU?

Do insiders and institutionals believe in JATT or CELU?

Is JATT or CELU more profitable?

Which has better earnings & valuation, JATT or CELU?

Do analysts recommend JATT or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools